ACF7 promotes spontaneous metastasis in HER2-driven breast cancer through cytoskeletal coordination

Breast cancer remains one of the most formidable challenges in modern medicine, not because the disease is impossible to treat, but because it has a deadly ability to spread. When cancer cells break away from a tumor in the breast and travel through the body to settle in distant organs like the lungs, the condition becomes far more difficult to manage. This process, known as metastasis, is the primary cause of death for patients with the disease. For decades, scientists have focused heavily on how tumors grow in size, yet the specific mechanisms that allow a single cell to detach, travel, and establish a new colony elsewhere have remained somewhat of a mystery. A critical part of this journey involves the cell's internal skeleton. Just as our own bodies rely on bones and muscles to move, individual cells use a network of protein filaments to push, pull, and change shape. Two of the most important parts of this internal framework are actin, which provides the force for movement, and microtubules, which act as rigid tracks that help the cell maintain its direction. For a cancer cell to migrate successfully, these two systems must work in perfect harmony, but the precise molecular switches that coordinate them during the spread of cancer have been difficult to pin down.

Researchers at the Montreal Clinical Research Institute and their colleagues have now identified a specific protein that acts as a vital coordinator for this internal machinery in a particularly aggressive form of breast cancer. This protein, called ACF7, serves as a bridge between the actin and microtubule networks. In a study published recently, the team investigated whether this protein was essential for the spread of tumors driven by a gene known as HER2, which is found in about 15 to 20 percent of breast cancer cases and is linked to a higher risk of recurrence. To answer this, the scientists created a genetically engineered mouse model that naturally developed breast tumors driven by the HER2 gene. They then bred these mice with another strain that lacked the gene for ACF7, but only in the mammary tissue. This allowed them to observe what happened when the protein was missing during the entire life cycle of the tumor, from its initial growth to its potential spread to the lungs.

The results revealed a striking and unexpected separation between how a tumor grows and how it spreads. When the researchers examined the mice without ACF7, they found that the primary tumors in the mammary glands grew just as large and developed just as quickly as those in the control mice. The number of tumors, their size, and the rate at which the cells divided were all essentially the same. The absence of ACF7 did not stop the cancer from forming or expanding within the breast. However, the story changed completely when they looked at the lungs. In the mice that lacked ACF7, the number of cancer cells that had traveled to the lungs and formed new metastatic lesions dropped by more than half. The protein was not needed for the cancer to get big, but it was absolutely critical for the cancer to get out. This finding suggests that the cellular tools required for a tumor to expand in place are different from the tools required for it to invade and travel to other parts of the body.

To understand why the cancer cells struggled to spread without ACF7, the researchers turned to the cells themselves. They took tumor cells from the mice and watched them move in the laboratory. Cells that still had ACF7 moved with purpose, extending their leading edges and gliding across surfaces with steady speed. In contrast, the cells missing ACF7 were sluggish and disorganized. They failed to coordinate their internal skeleton properly. Without the bridge that ACF7 provides, the microtubules, which usually stretch out toward the direction of travel, became straight and rigid, failing to follow the curves of the actin network. This lack of coordination meant the cells could not form the strong, temporary attachments to their surroundings that are necessary to pull themselves forward. They also had trouble turning over these attachments, leaving them stuck in place rather than letting go to move on. The researchers observed that the microtubules in these defective cells were also less stable and did not grow persistently in the right direction, further crippling the cell's ability to navigate.

The team confirmed these observations in a second, independent model of breast cancer cells, ensuring that the role of ACF7 was not unique to just one type of tumor. They also tested whether the protein helped the cancer cells survive after they had already entered the bloodstream. By injecting cancer cells directly into the veins of mice, bypassing the initial step of leaving the breast, they found that cells without ACF7 still struggled to colonize the lungs. This indicated that ACF7 is important not just for the initial escape from the tumor, but also for the later stages of the journey, such as surviving the trip through the blood and establishing a foothold in a new organ.

Finally, the researchers looked at human breast cancer samples to see if these findings held true in patients. They analyzed tissue from hundreds of women with breast cancer and found that ACF7 was present at high levels in tumors that were positive for the HER2 gene. More importantly, patients whose tumors had high levels of ACF7 were more likely to have the cancer spread to lymph nodes and distant organs like the bone, liver, lung, and brain. This correlation between high levels of the protein and the presence of metastasis in human patients supports the idea that ACF7 is a key driver of the disease's ability to spread.

The study does not suggest that ACF7 is a new drug target that can be immediately used to cure cancer, as the protein also plays important roles in normal body functions. However, it provides a clear genetic proof that the ability of a cancer cell to metastasize relies on a specific type of internal coordination that is distinct from the ability to simply grow. By identifying ACF7 as a linchpin in this process, the research highlights a potential vulnerability that could be exploited in the future. If scientists can find a way to disrupt the specific way ACF7 helps cancer cells move and invade without harming the cells' ability to divide, it might be possible to stop the spread of the disease while leaving the primary tumor intact. This approach could offer a new strategy for treating HER2-positive breast cancer, focusing not on shrinking the tumor, but on preventing it from ever reaching the lungs or other vital organs.